5 results
To determine the safety and efficacy of Dimebon in patients with mild to moderate Huntington Disease
To evaluate the long-term safety and tolerability of Dimebon in AD patients who have successfully completed 26 weeks of blinded treatment in the CONNECTION Study (DIM14) (hereafter referred to as *CONNECTION*).
To determine the benefit of Dimebon as compared to placebo on the primary measure of cognition and memory, the Alzheimer*s Disease Assessment Scale * cognitive subscale (ADAS-cog); andTo determine the benefit of Dimebon as compared to placebo on the…
Study phase A: Prospective Data CollectionObjectives: * What is the time weighted average spent in hypotension (defined as MAP<65 mmHg) during surgery? * What is normal treatment behaviour of hypotension during surgery? (Treatment choice,…
To evaluate the safety and performance of the Mobius HD system in subjects with resistant hypertension.